Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial

Delaloge, S; Cella, D; Ye, Y; Buyse, M; Chan, A; Barrios, C H; Holmes, F A; Mansi, J; Iwata, H; Ejlertsen, B; Moy, B; Chia, S K L; Gnant, M; Smichkoska, Snezhana; Ciceniene, A; Martinez, N; Filipović, S; Ben-Baruch, N E; Joy, A A; Langkjer, S T

doi:10.1093/annonc/mdz016

Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial

Journal

Annals of Oncology

Date Issued

2019

Author(s)

Delaloge, S

Cella, D

Ye, Y

Buyse, M

Chan, A

Barrios, C H

Holmes, F A

Mansi, J

Iwata, H

Ejlertsen, B

Moy, B

Chia, S K L

Gnant, M

Ciceniene, A

Martinez, N

Filipović, S

Ben-Baruch, N E

Joy, A A

Langkjer, S T

Senecal, F

de Boer, R H

Moran, S

Yao, B

Bryce, R

Auerbach, A

Fallowfield, L

Martin, M

DOI

10.1093/annonc/mdz016

Abstract

We report longitudinal health-related quality-of-life (HRQoL) data from the international, randomized, double-blind, placebo-controlled phase III ExteNET study, which demonstrated an invasive disease-free survival benefit of extended adjuvant therapy with neratinib over placebo in human epidermal growth factor receptor-2-positive early-stage breast cancer.

Subjects

early-stage breast ca...